Can osteosarcoma be cured? The chances of cure are better with earlier detection and treatment. Patients with osteosarcoma who are treated within the first year of diagnosis have an >8 times greater chance of cure. Patients with osteosarcoma of either genders have a better chance of cure if they are treated within the first year.
The most common symptoms of osteosarcoma are painless metastatic lesions in a child that do not respond to treatment, and an increasing grade/size of the primary lesion in the absence of signs of disease spread. The most common sites of metastatic lesions are the lungs and pelvis; less common sites are the thyroid, skin (primary, secondary), and bone (primary, secondary). It is necessary to rule out metastatic disease before the diagnosis of skeletal osteosarcoma is made.
Osteosarcoma is a rare cancer that forms in the bone. It typically arises in children and teenagers between the ages of 10 and 30 years old with boys being more often affected than girls. A history of heavy smoking may increase the risk. Osteosarcoma is a tumor that occurs in the bone, and presents as an abnormal shape in the bone that may become painful.
Recent findings defines common cancer treatments for osteosarcoma. All patients treated with a surgical resection are generally at some stage of clinical remission by one year after surgery. Radiotherapy is frequently an adjunctive treatment for patients who were not candidates for surgery. Chemotherapy and adjuvant therapy protocols vary greatly across the literature but are typically based on the local disease extent. We suggest that as the majority of patients with osteosarcoma are candidates for definitive surgical management, there is an opportunity for improvement in survival.
Studies have indicated that factors, in the environment as well as genetic, play an important role in the development of osteosarcoma. Smoking, alcohol, drugs, physical trauma, and infectious agents all may trigger an increased risk of developing this type of cancer. It is also known that the occurrence of osteosarcoma is less common in Asians than Caucasians.\n
Osteosarcoma does not seem to grow as rapidly as most cancers. However, the extent of the metastasis still varied significantly, and we have not seen much of a difference between the incidence of osteosarcoma cancer and metastatic osteosarcoma. All cases are treated with surgery though, however, in all patients there can be tumour cells in areas that are surgically inaccessible for long periods. We have seen a clear correlation in our patient pool with an increasing incidence of metastases over time, which is likely at least partly the result of our own treatment strategies rather than the presence of metastases on their own.
Cabozantinib s-malate inhibits Hsp90-mediated functions including chaperone gene expression in SKOV3 cell lines in vitro. Further in vivo studies are warranted to clarify its effects, and if effective, its role in bone and tissue regeneration.
Cabozantinib, which acts as MET and VEGFR2 dual kinase inhibitor, is an effective treatment in a subset of patients with advanced sarcoma. It will be interesting to see how many patients respond to a second dosing of cabozantinib.
Although there were no clear disparities between treatment facilities, the survival rate of osteosarcoma patients was not higher than that for other cancer patients. The low prevalence of distant metastases is the most important prognostic factor. We should, perhaps, consider a more aggressive treatment strategy for patients who have metastases.
This agent is a promising therapy for patients with RAS wild-type advanced or metastatic solid tumors but has not finished phase III clinical trials. Further studies have suggested its activity as a single-agent, first-line treatment for metastatic renal cell carcinoma (RCC) patients and warrants further clinical study.
This is very important because one should be on the lookout for new developments in the disease. There is new research for osteosarcoma that may yield more information on some prognostic factors of the disease and also its treatment. It is clear from this research that the prognosis still remains the same but our knowledge about the condition has grown bigger and better. For research to go ahead smoothly we need to come together and work together to raise the levels of awareness for our condition and get our voice heard.